Pharmacology of amineptine: Synthesis and updating

S. Garattini, T. Mennini

Research output: Contribution to journalArticle

Abstract

Amineptine is a tricyclic antidepressant agent with the unique capacity to decrease selectively the uptake of dopamine (DA) without affecting the uptake of noradrenaline (NA) and serotonin (5HT). The effect is obtained both in vitro and in vivo by the use of suitable methodology. Amineptine can be differentiated from amphetamine both on the basis of pharmacological as well as biochemical parameters. In vivo, amineptine increases striatal homovanillic acid without affecting the levels of other metabolites of DA, namely, 3, 4, dihydrozoxyphenylacetic acid (DOPAC) and 3-methoxytramine (3MT). However, by using relatively high doses of amineptine, the extracellular DOPAC level - assessed by the use of pulse voltammetry - was decreased preferentially in the nucleus accumbens but not in the striatum. Chronic treatment with amineptine, as with other antidepressant agents, induces a down-regulation of β-adrenergic receptors. Amineptine enters the brain and its pharmacological effects are likely due to the unchanged drug rather than to its two main metabolites.

Original languageEnglish
JournalClinical Neuropharmacology
Volume12
Issue numberSUPPL. 2
Publication statusPublished - 1989

Fingerprint

amineptin
Pharmacology
Dopamine
Corpus Striatum
Homovanillic Acid
Acids
Tricyclic Antidepressive Agents
Nucleus Accumbens
Amphetamine
Adrenergic Receptors
Antidepressive Agents
Serotonin
Norepinephrine
Down-Regulation

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacology of amineptine : Synthesis and updating. / Garattini, S.; Mennini, T.

In: Clinical Neuropharmacology, Vol. 12, No. SUPPL. 2, 1989.

Research output: Contribution to journalArticle

@article{967706e47e814403850d67599bb77ccf,
title = "Pharmacology of amineptine: Synthesis and updating",
abstract = "Amineptine is a tricyclic antidepressant agent with the unique capacity to decrease selectively the uptake of dopamine (DA) without affecting the uptake of noradrenaline (NA) and serotonin (5HT). The effect is obtained both in vitro and in vivo by the use of suitable methodology. Amineptine can be differentiated from amphetamine both on the basis of pharmacological as well as biochemical parameters. In vivo, amineptine increases striatal homovanillic acid without affecting the levels of other metabolites of DA, namely, 3, 4, dihydrozoxyphenylacetic acid (DOPAC) and 3-methoxytramine (3MT). However, by using relatively high doses of amineptine, the extracellular DOPAC level - assessed by the use of pulse voltammetry - was decreased preferentially in the nucleus accumbens but not in the striatum. Chronic treatment with amineptine, as with other antidepressant agents, induces a down-regulation of β-adrenergic receptors. Amineptine enters the brain and its pharmacological effects are likely due to the unchanged drug rather than to its two main metabolites.",
author = "S. Garattini and T. Mennini",
year = "1989",
language = "English",
volume = "12",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Pharmacology of amineptine

T2 - Synthesis and updating

AU - Garattini, S.

AU - Mennini, T.

PY - 1989

Y1 - 1989

N2 - Amineptine is a tricyclic antidepressant agent with the unique capacity to decrease selectively the uptake of dopamine (DA) without affecting the uptake of noradrenaline (NA) and serotonin (5HT). The effect is obtained both in vitro and in vivo by the use of suitable methodology. Amineptine can be differentiated from amphetamine both on the basis of pharmacological as well as biochemical parameters. In vivo, amineptine increases striatal homovanillic acid without affecting the levels of other metabolites of DA, namely, 3, 4, dihydrozoxyphenylacetic acid (DOPAC) and 3-methoxytramine (3MT). However, by using relatively high doses of amineptine, the extracellular DOPAC level - assessed by the use of pulse voltammetry - was decreased preferentially in the nucleus accumbens but not in the striatum. Chronic treatment with amineptine, as with other antidepressant agents, induces a down-regulation of β-adrenergic receptors. Amineptine enters the brain and its pharmacological effects are likely due to the unchanged drug rather than to its two main metabolites.

AB - Amineptine is a tricyclic antidepressant agent with the unique capacity to decrease selectively the uptake of dopamine (DA) without affecting the uptake of noradrenaline (NA) and serotonin (5HT). The effect is obtained both in vitro and in vivo by the use of suitable methodology. Amineptine can be differentiated from amphetamine both on the basis of pharmacological as well as biochemical parameters. In vivo, amineptine increases striatal homovanillic acid without affecting the levels of other metabolites of DA, namely, 3, 4, dihydrozoxyphenylacetic acid (DOPAC) and 3-methoxytramine (3MT). However, by using relatively high doses of amineptine, the extracellular DOPAC level - assessed by the use of pulse voltammetry - was decreased preferentially in the nucleus accumbens but not in the striatum. Chronic treatment with amineptine, as with other antidepressant agents, induces a down-regulation of β-adrenergic receptors. Amineptine enters the brain and its pharmacological effects are likely due to the unchanged drug rather than to its two main metabolites.

UR - http://www.scopus.com/inward/record.url?scp=0024946958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024946958&partnerID=8YFLogxK

M3 - Article

C2 - 2698268

AN - SCOPUS:0024946958

VL - 12

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - SUPPL. 2

ER -